Entering the Calculated 10-Year ASCVD Risk Score
A single risk-equation output starts the entire initiation decision.
- Pooled Cohort Eq.: Risk tool (ACC/AHA risk calculator)
- 40–75 yrs: Validated age range (Primary prevention population)
- 7 variables: Inputs used (Age, sex, lipids, BP, smoking, diabetes)
- 10-yr % risk: Output (Continuous risk estimate)
Where the risk number comes from
A short placeholder: risk equation output feeds this simulator directly.
Placing Risk Into Low, Borderline, Intermediate, or High Zones
Four guideline zones split the risk scale at fixed cut points.
- <5%: Low zone (Statin not routinely indicated)
- 5–7.5%: Borderline zone (Enhancers may tip decision)
- 7.5–20%: Intermediate zone (Shared decision-making zone)
- ≥20%: High zone (Statin strongly recommended)
How the zone boundaries were set
A short placeholder: cut points come from outcome-trial risk stratification.
Checking Risk-Enhancing Factors Beyond the Base Score
Extra clinical flags refine decisions in borderline and intermediate cases.
- Premature ASCVD: Family history (Risk-enhancer flag)
- ≥2.0 mg/L: hs-CRP (Risk-enhancer flag)
- CAC score >0: Coronary calcium (Risk-enhancer flag)
- Present: Metabolic syndrome (Risk-enhancer flag)
Why enhancers matter at the margins
A short placeholder: enhancers tip borderline patients toward treatment.
Shared Decision-Making Within the Intermediate Risk Band
Patient preference and enhancers jointly guide the intermediate-zone call.
- 7.5–20%: Applicable range (Intermediate risk band)
- Benefits vs risks: Discussion topics (Bleeding, myalgia, cost)
- Yes: Enhancer tiebreaker (Tips toward statin use)
- Weighted input: Patient preference (Final decision factor)
What the shared discussion covers
A short placeholder: clinician and patient weigh risk and preference together.
Issuing the Statin Initiation and Intensity Recommendation
Combined risk zone and enhancer count yield one clear recommendation.
- High-intensity: High risk (≥20% 10-year risk)
- Moderate: Intermediate + enhancers (Statin favored)
- Not indicated: Low risk (Unless enhancers present)
- Lipid recheck: Follow-up (4–12 weeks after start)
Reading the final recommendation
A short placeholder: recommendation strength scales with risk and enhancers.
This tool supports, not replaces, individualized clinician judgment.